scholarly journals CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients

Oncotarget ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 20328-20339 ◽  
Author(s):  
Yifan Cao ◽  
Hao Liu ◽  
Heng Zhang ◽  
Chao Lin ◽  
Ruochen Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Chemokine Receptor ◽  
Postoperative Prognosis ◽  
Cxc Chemokine ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients ◽  
Chemokine Receptor 1

scholarly journals The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Zhenglin Wang ◽  
Hao Liu ◽  
Zhenbin Shen ◽  
Xuefei Wang ◽  
Heng Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Chemokine Receptor ◽  
Prognostic Value ◽  
Cxc Chemokine ◽  
Gastric Cancer Patients

scholarly journals Efficacy and Safety of FLOT regimen vs. DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients

2021 ◽  
Author(s):  
Pegah Farrokhi ◽  
Alireza Sadeghi ◽  
Mehran sharifi ◽  
Payam Dadvand ◽  
Rachel Riechelmann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cox Regression ◽  
Progression Free Survival ◽  
R0 Resection ◽  
P Value ◽  
Perioperative Chemotherapy ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

AbstractAimThis study aimed to evaluate and compare the efficacy and toxicity of common regimens used as perioperative chemotherapy including ECF, DCF, FOLFOX, and FLOT to identify the most effective chemotherapy regimen with less toxicity.Material and MethodsThis retrospective cohort study was based on 152 eligible gastric cancer patients recruited in a tertiary oncology hospital in Isfahan, Iran (2014-2019). All resectable gastric cancer patients who had received one of the four chemotherapy regimens including ECF, DCF, FOLFOX, or FLOT, and followed for at least one year (up to five years) were included. The primary endpoint of this study was Overall Survival (OS), Progression-Free Survival (PFS), Overall Response Rate (ORR), and R0 resection. We also considered toxicity according to CTCAE (v.4.0) criteria as a secondary endpoint. Cox -regression models were used applied to estimate OS and PFS time, controlled for relevant covariates.ResultsOf included patients, 32(21%), 51(33.7%), 37(24.3%), and 32(21%) had received ECF, DCF, FOLFOX and FLOT, respectively. After the median 25 months follow-up, overall survival was higher with the FLOT regimen in comparison with other regimens (hazard ratio [HR] = 0. 052). The median OS of the FLOT regimen was not reachable in Kaplan-Meier analysis and the median OS was 28, 26, and 23 months for DCF, FOLOFX, and ECF regimens, respectively. On the other hand, a median PFS of 25, 17, 15, and 14 months was observed for FLOT, DCF, FOLFOX, and ECF regimens, respectively (Log-rank = 0. 021). FLOT regimen showed 84. 4% ORR which was notably higher than other groups (p-value<0. 01).ConclusionsFor resectable gastric cancer patients, the perioperative FLOT regimen seemed to lead to a significant improvement in patients’ OS and PFS in comparison with ECF, DCF, and FOLFOX regimens. As such, the FLOT regimen could be considered as the optimal option for managing resectable gastric cancer patients.

scholarly journals Decreased albumin-to-alkaline phosphatase ratio predicted poor survival of resectable gastric cancer patients

2021 ◽  
Vol 12 (4) ◽  
pp. 1338-1350
Author(s):  
Yan Wang ◽  
Feng Xiong ◽  
Jian Yang ◽  
Tingting Xia ◽  
Zhenyu Jia ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Alkaline Phosphatase ◽  
Cancer Patients ◽  
Poor Survival ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

Prognostic Value of Preoperative Clinical Staging Assessed by Computed Tomography in Resectable Gastric Cancer Patients

2010 ◽  
Vol 251 (3) ◽  
pp. 428-435 ◽  
Author(s):  
Sook Ryun Park ◽  
Min Ju Kim ◽  
Keun Won Ryu ◽  
Jun Ho Lee ◽  
Jong Seok Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Computed Tomography ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Clinical Staging ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

scholarly journals Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients

Medicine ◽  
2018 ◽  
Vol 97 (52) ◽  
pp. e13896 ◽  
Author(s):  
Yu-Chen Pan ◽  
Zhi-Fang Jia ◽  
Dong-Hui Cao ◽  
Yan-Hua Wu ◽  
Jing Jiang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Lymphocyte To Monocyte Ratio ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients

2013 ◽  
Vol 49 (11) ◽  
pp. 1441-1452 ◽  
Author(s):  
Yefei Huang ◽  
Weimin Wang ◽  
Yansu Chen ◽  
Yulin Huang ◽  
Jianbing Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

Optimal cycles of fluoropyrimidine-based adjuvant chemotherapy for patients with resectable gastric cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15160-e15160
Author(s):  
Yunpeng Liu ◽  
Xiujuan Qu ◽  
Jinglei Qu ◽  
Jingdong Zhang ◽  
Jing Liu
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Duration Of Treatment ◽  
D2 Lymph Node Dissection ◽  
Adult Age ◽  
Clinical Covariates ◽  
Resectable Gastric Cancer ◽  
Gastric Cancer Patients

e15160 Background: Although several clinical trials have suggested that postoperative adjuvant chemotherapy could improve survival, there has no study on the optimal cycles of treatment. This retrospective analysis was carried out to evaluate the outcomes of gastric cancer patients treated with 5-6 cycles of FU-based treatment as compared to a cohort treated with 3-4 cycles or 7-8 cycles. Methods: We retrospective identified 254 patients with stage IB-IIIC gastric cancer who received 3-8 cycles of adjuvant chemotherapy after gastrectomy with D1 or D2 lymphadenectomy. The endpoint was overall survival. Factors associated with prognosis were also analyzed. Results: Of the 254 patients, 74 patients treated with 3-4 cycles, 112 patients treated with 5-6 cycles and 68 patients treated with 7-8 cycles. The 3-year OS rates for 3-4 cycles, 5-6 cycles and 7-8 cycles cohort was 56.6%, 73.9% and 67.7%, respectively. Patients who received 5-6 cycles were more likely to have better OS than those received 3-4 cycles (p=0.003), two further cycles of treatment did not improved OS (p=0.885). In the multivariate analysis, cycles of chemotherapy were associated with OS independent of clinical covariates (p=0.008). Subgroup analysis was suggested that for patients with older adult (age ≥60), FU-platinum combined chemotherapy, stage III, poorly differentiation, and gastrectomy with D2 lymph node dissection, 5-6 cycles of adjuvant chemotherapy was associated with a statistically significant benefit of OS (P<0.05). Conclusions: Our result indicated that 5-6 cycles of adjuvant chemotherapy may lead to a favorable outcome for gastric cancer patients following primary surgical treatment. In view of the limited resources of medication, reduced incidences of toxicity and better quality-of-life with shorter duration of treatment, optimal cycles of adjuvant treatment should be explored further.

Sign in / Sign up

Export Citation Format

Share Document